What FutureNeuro does

FutureNeuro is the Research Ireland Centre for Translational Brain Science, hosted at RCSI University of Medicine and Health Sciences in Dublin, Ireland. Founded in 2017, it operates as a multi-institutional research centre spanning eight Irish universities (RCSI, Trinity College Dublin, University College Dublin, University College Cork, University of Galway, Dublin City University, Maynooth University, and South East Technological University) and maintains a national clinical network across major hospitals including Beaumont Hospital, St James' Hospital, Children's Health Ireland Crumlin, and Cork University Hospital. Its research targets neurological, neurodevelopmental, and neuropsychiatric conditions — principally epilepsy, ALS, multiple sclerosis, Parkinson's disease, psychosis, and rare autoimmune epilepsies — organised into three thematic programmes: Diagnostics, Therapeutics, and Digital Health.

The centre's technology footprint comprises several proprietary preclinical and translational platforms. The DELFIN platform is positioned as the first method capable of evolving long non-coding RNAs (lncRNAs) inside their natural cellular environment to map sequence-function relationships and engineer therapeutic RNA molecules. The MicroRNA-134 inhibition programme targets drug-resistant temporal lobe epilepsy by attenuating single-neuron and network hyperexcitability. The T-CARE OVA-ALE mouse model validates next-generation anti-CD3 monoclonal antibodies for autoimmune encephalitis and Rasmussen's encephalitis. A large-scale proteomics study analyses nearly 11,000 proteins across plasma samples from more than 500 participants to identify biomarkers for personalised treatment in first-episode psychosis. The MX-REGEN project develops MXene-functionalised 3D-printed electroconductive scaffolds for spatially controlled pro-regenerative electrical stimulation in neurotrauma. Additional research lines include P2X7 receptor mechanisms in post-traumatic hyperexcitability and tsRNA biomarker discovery for epilepsy and neurodegeneration. Publications have appeared in high-impact venues including Science Translational Medicine.

FutureNeuro does not sell commercial products or services and has no disclosed pricing model. Revenue derives from competitive research grants, with Research Ireland as the core anchor funder (as the national Research Ireland Centre), supplemented by the European Research Council (including a €2.5 million ERC Advanced Grant), the European Rare Diseases Research Alliance (ERDERA), the Royal Society, Science Foundation Ireland/Irish Research Council (SFI-IRC Pathway), and the Lister Institute of Preventive Medicine. Industry engagement is structured around technology licensing, co-development, and commercialisation pathways rather than direct sales. The centre's stakeholders comprise patients with neurological conditions, clinical and academic researchers across the eight partner institutions, pharmaceutical and medtech industry partners, and the Irish public through PPI programmes and the My Moving Brain community initiative.

Name

FutureNeuro

Legal name

FutureNeuro

Website

https://futureneurocentre.ie

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

FutureNeuro is Ireland's Research Ireland Centre for Translational Brain Science, spanning eight universities and a national clinical network. It conducts translational research on epilepsy, ALS, MS, Parkinson's, psychosis, and rare neurological conditions, funded by competitive government grants.

Ownership category

akta.pro rank

Product category

Translational Neuroscience Research

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurogenetics & Rare Neurologic Diseases (HLAKAIAO)

akta.pro secondary industries

Movement Disorders (Parkinson’s, Tremor, Dystonia) (HLAKAIAC), Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC), Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

Keywords

• Translational brain science
• Neurological disease research
• Epilepsy research
• Proteomics biomarker discovery
• Digital health therapeutics

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Research Funding and Grants: FutureNeuro is funded primarily through competitive research grants from government and international funding bodies including Research Ireland, European Research Council (ERC), European Rare Diseases Research Alliance (ERDERA), Royal Society, and other scientific funding agencies. The center receives core funding as a Research Ireland Centre for Translational Brain Science.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

FutureNeuro is Ireland's Research Ireland Centre for Translational Brain Science, conducting multi-disciplinary preclinical and clinical research across neurological, neurodevelopmental, and neuropsychiatric conditions including epilepsy, ALS, MS, Parkinson's disease, and psychosis. The center operates across eight academic partner institutions and a national clinical network, delivering research outputs across three thematic areas: Diagnostics, Therapeutics, and Digital Health. It also runs community engagement programs such as My Moving Brain and provides industry collaboration pathways for technology licensing and commercialization.

Product overview

FutureNeuro is the Research Ireland Centre for Translational Brain Science, hosted by RCSI University of Medicine and Health Sciences. It operates as a multi-institutional research center (spanning eight universities and a national clinical network) rather than a commercial product company. The center's offerings consist of research programmes organized across three thematic areas: Diagnostics, Therapeutics, and Digital Health. Key initiatives include My Moving Brain (a community engagement initiative promoting brain health through inclusive sport) and NeuroAdapt/PSI-STAR (psychosis research training programmes). The center also conducts large-scale proteomics studies and publishes research breakthroughs in epilepsy, ALS, MS, Parkinson's disease, and psychiatric conditions. The organization engages with industry partners for commercialization but does not offer commercial products or services in the traditional sense.

Differentiator

Problem solved

Functional benefit

Products and services

• Large-Scale Proteomics Study for First-Episode Psychosis A research study analyzing nearly 11,000 proteins across plasma samples from over 500 participants to identify biological markers that predict treatment response in first-episode psychosis. Led by Professor David Cotter at RCSI, the study aims to enable personalized treatment selection for patients with psychotic disorders.
• My Moving Brain A national, community-driven initiative funded by Research Ireland that promotes brain health awareness and inclusivity in sport for individuals impacted by brain conditions across Ireland through Community Connect events in Dublin, Cork, Kildare, and Galway.
• Community Connect Events A series of regional events held across Ireland (Dublin, Cork, Kildare, Galway) that bring together individuals, families, sports clubs, clinicians and researchers to explore inclusive sport for people with brain conditions.

Quantifiable outcome

• Large-scale proteomics study analyzing nearly 11,000 proteins across 500+ participants to identify biomarkers for personalized psychosis treatment
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

21 partnerships are on record, tiered core and minor.

• RCSI University of Medicine and Health SciencescoreStrategic or Co-development PartnerHost institute of FutureNeuro, providing the primary institutional base and leadership for the research center. RCSI houses the Centre Director and core operational team.
• Trinity College DublincoreStrategic or Co-development PartnerPartner university contributing researchers including Prof Colin Doherty and Prof Mark Cunningham. Researchers focus on neurophysiology, digital health, and epilepsy research.
• University College DublincoreStrategic or Co-development PartnerPartner university housing Prof Rory Johnson (ERC Advanced Grant recipient) for long non-coding RNA research and Catherine Mooney for biomarker research.
• University College CorkcoreStrategic or Co-development PartnerPartner university contributing Dr Daniel Costello and the epilepsy service at Cork University Hospital.
• University of GalwaycoreStrategic or Co-development PartnerPartner university contributing Prof David Finn and researchers focusing on neurodegenerative disorders and bioinformatics.
• Dublin City UniversitycoreStrategic or Co-development PartnerPartner university collaborating through Insight SFI Research Centre on the NeuroInsight COFUND fellowship program.
• Maynooth UniversitycoreStrategic or Co-development PartnerPartner university contributing to the multi-institutional FutureNeuro research network.
• South East Technological UniversitycoreStrategic or Co-development PartnerPartner university contributing to the FutureNeuro multi-institutional research network.
• Beaumont HospitalcoreStrategic or Co-development PartnerMajor clinical partner hospital where Prof David Cotter serves as Consultant Psychiatrist. Site for human brain slice models and clinical research.
• St James' HospitalcoreStrategic or Co-development PartnerClinical partner hospital where Dr Colin Doherty is based and epilepsy services are delivered.
• Children's Health Ireland CrumlincoreStrategic or Co-development PartnerPediatric clinical partner contributing to research on childhood neurological conditions.
• Cork University HospitalcoreStrategic or Co-development PartnerRegional clinical partner where Dr Daniel Costello established the epilepsy service including first seizure clinic and epilepsy monitoring unit.
• Brokentalkers Theatre CompanyminorStrategic or Co-development PartnerCollaboration on 'The Mirror Stage' theatre production about lived experience of psychosis, developed with FutureNeuro Principal Investigators Prof David Cotter and Prof Mary Cannon, funded by Arts Council of Ireland.
• Heinrich-Heine University (Germany)coreStrategic or Co-development PartnerT-CARE consortium coordinator led by Dr Nico Melzer, partnering with FutureNeuro on international rare autoimmune epilepsy research.
• CDKL5 AllianceminorStrategic or Co-development PartnerPatient advocacy organization collaborating with Dr Omar Mamad on CDKL5 Deficiency Disorder research awareness and understanding.
• Epilepsy IrelandminorStrategic or Co-development PartnerPatient advocacy organization partnering on My Moving Brain community initiative and epilepsy awareness activities.
• Neurological Alliance of Ireland (NAI)minorStrategic or Co-development PartnerNational umbrella organization for neurological charities, represented by Magdalen Rogers on My Moving Brain steering group.
• Dun Laoghaire Rathdown Sports Partnership (DLRSP)minorStrategic or Co-development PartnerLocal sports partnership collaborating on My Moving Brain inclusive sport initiatives and epilepsy awareness training.
• Insight SFI Research Centre for Data AnalyticscoreStrategic or Co-development PartnerCOFUND partner in the NeuroInsight postdoctoral fellowship program alongside FutureNeuro, supervised by Prof Tomas Ward.
• PSI-STAR Programme at RCSIminorStrategic or Co-development PartnerPsychosis Ireland Structured Training and Research Programme used for engaging individuals with lived experience of psychosis for theatre collaboration.
• T-CARE Consortium PartnerscoreStrategic or Co-development PartnerSix institutions across Germany, Italy, Switzerland, Ireland, and Türkiye collaborating on T-CARE international project for autoimmune encephalitis and Rasmussen's encephalitis research.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Biogen: Global biopharmaceutical company focused on neurological and neurodegenerative diseases (MS, ALS, Alzheimer's, Parkinson's). Comparable as a large player operating broadly in the same disease areas FutureNeuro's translational pipeline targets, with overlapping therapeutic modalities including RNA-based and monoclonal antibody approaches.
• Eisai Co., Ltd. Global pharmaceutical company with a strong neurology franchise (epilepsy, Alzheimer's, Parkinson's). Comparable as a large incumbent whose disease focus substantially overlaps with FutureNeuro's therapeutic priorities and whose industry-partnering model FutureNeuro targets for commercialisation.
• UCB (Union Chimique Belge): Global biopharma with deep neurology franchises in epilepsy and rare neurological disorders. Comparable as a major industry partner candidate for FutureNeuro's epilepsy and rare-disease programmes and as an established player working in the same therapeutic indications.

Direct peers

• Queensland Brain Institute: University-based neuroscience research institute focused on understanding and treating brain disorders through multi-disciplinary research. Comparable as a translational neuroscience research hub combining basic discovery and clinical translation across neurological and psychiatric conditions.
• Allen Institute for Brain Science: Large-scale independent neuroscience research organisation producing open, high-impact datasets and tools. Comparable in scale and ambition of translational brain science and emphasis on data-driven discovery across neurological diseases.
• Neuroscience Research Australia (NeuRA): Independent medical research institute focused on neuroscience and translational research across neurological and psychiatric disorders. Comparable as a not-for-profit translational brain research centre with multiple research programmes and clinical partnerships.
• UK Dementia Research Institute: National translational neuroscience research centre in the UK funded by charity and government grants. Comparable to FutureNeuro in mission (translational brain science across multiple universities and disease areas), funding model (multi-institutional research grants) and patient/public involvement emphasis.
• Karolinska Institutet – Department of Neuroscience: Major European academic neuroscience department conducting preclinical and clinical brain research across neurological disorders. Comparable in the breadth of disease focus (epilepsy, MS, Parkinson's, ALS-style neurodegeneration) and translational approach.

Emerging players

• Praxis Precision Medicines: Clinical-stage biotechnology company developing therapies for central nervous system disorders, with a notable focus on epilepsy. Comparable as a focused neuro-focused emerging biotech whose translational pipeline (especially in drug-resistant epilepsy) directly intersects with FutureNeuro's microRNA-134 and autoimmune epilepsy programmes.
• Ionis Pharmaceuticals: RNA-targeted therapeutics company with multiple neurology programmes across ALS, Huntington's and rare neurological diseases. Comparable as a leader in RNA-based drug discovery whose technology base overlaps with FutureNeuro's lncRNA (DELFIN) and microRNA-134 inhibitor work and which represents a plausible partner or acquirer of those research outputs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Futureneuro_ie
• Facebookfacebook.com/FutureNeuroCentre
• LinkedInlinkedin.com/company/futureneuro

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FutureNeuro